{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:59:27Z","timestamp":1775059167975,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The prognosis of <jats:italic>MECOM<\/jats:italic>r AML is poor, with a 5-year overall survival (OS) rate of less than 10%. This is mostly attributable to the low efficacy of all available therapies and high relapse rates even after allogeneic stem cell transplantation (alloSCT), which remains the only curative approach. We report upfront sequential alloSCT with venetoclax-based preconditioning as a safe and effective treatment for two newly diagnosed and fit <jats:italic>MECOM<\/jats:italic>r AML patients. The sequential alloSCT regimen consisted of triple therapy: preconditioning with decitabine and venetoclax on days 1\u20135 followed by FLAG-Ida and venetoclax on days 6\u201310. One or 3 days after preconditioning, the patients underwent busulfan-based myeloablative conditioning and HLA haploidentical or matched related donor stem cell infusion. One month after alloSCT, timely engraftment and complete remission were achieved. At the last follow-up, both patients were in good health and in MRD-negative complete remissions after 11 and 17 months after alloSCT, respectively. The safety and efficacy of upfront sequential alloSCT indicate the need to evaluate this approach for adverse risk of AML in clinical trials.<\/jats:p>","DOI":"10.3389\/fonc.2025.1530852","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T23:45:23Z","timestamp":1743119123000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Decitabine and venetoclax sequentially followed by FLAG-Ida and venetoclax with immediate allogeneic stem cell transplantation in newly diagnosed acute myeloid leukemia with chromosome 3 inversion\/MECOM rearrangement"],"prefix":"10.3389","volume":"15","author":[{"given":"Andrius","family":"\u017du\u010denka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milvyd\u0117","family":"Tamutyt\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/cancers15020458","article-title":"3q26.2\/MECOM rearrangements by pericentric inv(3): diagnostic challenges and clinicopathologic features","volume":"15","author":"Tang","year":"2023","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282030","article-title":"Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)","volume":"108","author":"Richard-Carpentier","year":"2023","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2367040","article-title":"Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome","volume":"65","author":"Alhajahjeh","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B4","unstructured":"Inv(3)(q21q26) GATA2::MECOM t(3;3)(q21;q26) GATA2::MECOM ins(3;3)(q26;q21q26) GATA2::MECOM"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.v105.2","article-title":"Acute myeloid leukemia with inv(3)(q21.3q26.2)\/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols","volume":"105","author":"Sitges","year":"2020","journal-title":"Eur J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.v90.10","article-title":"Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities","volume":"90","author":"Wanquet","year":"2015","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1182\/blood-2023-180100","article-title":"Clinical characteristics and outcomes of myeloid neoplasms with mecom rearrangement: results from a nationwide multicenter study","volume":"142","author":"Polprasert","year":"2023","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0165-x","article-title":"AlloHSCT for inv(3)(q21;q26)\/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation","volume":"53","author":"Halaburda","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8898671","DOI":"10.1155\/2021\/8898671","article-title":"Concurrent central diabetes insipidus and acute myeloid leukemia","volume":"2021","author":"Pritzl","year":"2021","journal-title":"Case Rep Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12257","article-title":"Acute myeloid leukemia with diabetes insipidus and hypophyseal infiltration","volume":"12","author":"Harrup","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood-2010-04-281337","article-title":"Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1","volume":"117","author":"Lugthart","year":"2010","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025370","article-title":"Acetylation of the proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis","volume":"6","author":"Pradhan","year":"2011","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/cancers16061091","article-title":"Venetoclax resistance in acute myeloid leukemia","volume":"16","author":"Garciaz","year":"2024","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discovery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41408-021-00457-9","article-title":"EVI1 dysregulation: impact on biology and therapy of myeloid Malignancies","volume":"11","author":"Birdwell","year":"2021","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13148-024-01677-z","article-title":"Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children","volume":"16","author":"Zhang","year":"2024","journal-title":"Clin Epigenet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087475","article-title":"Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia","volume":"9","author":"Leonard","year":"2014","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1728754","article-title":"Randomized phase 1 study of sequential (\u201cprimed\u201d) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed\/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm","volume":"61","author":"Palmieri","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6519","article-title":"FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed\/refractory (RR) AML","volume":"42","author":"Jen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6499","article-title":"Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories","volume":"30","author":"Cornelissen","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bbmt.2014.10.026","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"21","author":"Vyas","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v205.1","article-title":"Early blast clearance during sequential conditioning before allogeneic stem cell transplantation in patients with acute myeloid leukaemia","volume":"205","author":"Ronnacker","year":"2024","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.226","article-title":"Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial","volume":"30","author":"Middeke","year":"2016","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.142","article-title":"Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia","volume":"27","author":"St\u00f6lzel","year":"2013","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.07.018","article-title":"FLAMSA-busulfan-melphalan as a sequential conditioning regimen in HLA-matched or haploidentical hematopoietic stem cell transplantation for high-risk myeloid diseases","volume":"27","author":"Jondreville","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.07.020","article-title":"FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed\/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"26","author":"Rodr\u00edguez-Arbol\u00ed","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1774-5","article-title":"Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia","volume":"92","author":"Schneidawind","year":"2013","journal-title":"Ann Hematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/bmt.2011.15","article-title":"Early allo-SCT for AML with a complex aberrant karyotype\u2013results from a prospective pilot study","volume":"47","author":"Schmid","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.09.006","article-title":"Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen","volume":"18","author":"Saure","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1182\/blood-2024-203229","article-title":"Individualized sequential allogeneic stem cell transplantation for relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome patients with active disease","volume":"144","author":"Zucenka","year":"2024","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1530852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T23:45:26Z","timestamp":1743119126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1530852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":37,"alternative-id":["10.3389\/fonc.2025.1530852"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1530852","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"article-number":"1530852"}}